Prelude Therapeutics Incorporated
NASDAQ:PRLDBiotechnology
-$0.14 today
- Market cap
- $192.16M
- Beta
- 1.01
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.94
Volume 0.42M
Average 0.38M
Returns on capital
Prelude Therapeutics Incorporated management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-145.0%
avg -37.2%
ROIC
-114.8%
avg -82.1%
ROA
-70.4%
avg -64.6%
Analysis
ROA is currently the strongest return metric at -70.4% versus its period average of -64.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Krishna Vaddi | Founder, Chief Executive Officer & Director | USD 935.26K | 60 | 837.00K | 1.07% |
Bryant David Lim | Chief Financial Officer, Chief Legal Officer & Corporate Secretary | USD 681.05K | 55 | 275.00K | 0.35% |
Peggy A. Scherle | Chief Scientific Officer | USD 674.21K | 64 | — | — |
Andrew Combs | Executive Vice President & Chief Chemistry Officer | USD 562.46K | 59 | 230.00K | 0.29% |
Wan-Jen Hong | Senior Vice President of Clinical Development | — | 47 | — | — |
Michele Porreca | Chief People Officer | — | — | — | — |
Madhu Pudipeddi | Senior Vice President of Technical Operations | — | — | — | — |
Naveen Babbar | Senior Vice President of Translation Medicine | — | — | — | — |
Robert A. Doody Jr. | Senior Vice President of Investor Relations | — | — | — | — |
Aimee Crombie | Senior Vice President and Head of Strategic Planning & Operations | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Feb 4, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
6
$25.00M
Sells
0
$0.00
Net Transaction Value
+$25.00M
Net buying
Most Active
Bonita David P
2 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Apr 21, 26Apr 21, 2026 | Bonita David P Indirect | Buy | $7.5M$7,499,999.16 |
| Apr 21, 26Apr 21, 2026 | Bonita David P Indirect | Buy | $5M$4,999,999.44 |
| Apr 21, 26Apr 21, 2026 | ORBIMED ADVISORS LLC Indirect | Buy | $7.5M$7,499,999.16 |
| Apr 21, 26Apr 21, 2026 | ORBIMED ADVISORS LLC Indirect | Buy | $5M$4,999,999.44 |
| Apr 21, 26Apr 21, 2026 | BAKER BROS. ADVISORS LP Indirect | Buy | $213.8$213.77 |
| Apr 21, 26Apr 21, 2026 | BAKER BROS. ADVISORS LP Indirect | Buy | $11.5$11.46 |
Summary
Insiders reported 6 buys worth $25.00M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $25.00M. Bonita David P was the most active insider with 2 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +52.5% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at +52.5% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does Prelude Therapeutics Incorporated compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about PRLD's management, answered from reported figures.
Who manages PRLD?
Prelude Therapeutics Incorporated (PRLD) lists 10 active executives. The top listed executive is Wan-Jen Hong, Senior Vice President of Clinical Development.
Are PRLD insiders buying or selling?
Recent insider activity shows net buying of $66.92M.
Continue the stock analysis
Jump to another research area for this company.